Myelodysplastic Syndromes: Drugs

(asked on 15th June 2021) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to tackle regional disparities in drug access for MDS patients in England.


Answered by
Jo Churchill Portrait
Jo Churchill
Minister of State (Department for Work and Pensions)
This question was answered on 21st June 2021

The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing evidence-based guidance for the National Health Service on whether medicines represent a clinically and cost-effective use of resources. NICE has published guidance recommending azacitidine for the treatment of myelodysplastic syndromes (MDS), and lenalidomide for treating MDS associated with an isolated deletion 5q cytogenetic abnormality. The NHS in England is legally required to fund medicines recommended in a NICE appraisal and both medicines are routinely funded by NHS England and NHS Improvement for eligible patients in line with NICE’s recommendations.

Reticulating Splines